Skip to main content

Table 1 Baseline demographics, disease characteristics and comorbidities (analysis population)

From: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

Characteristic N = 865
Demographics
Age N = 865
  Mean (SD), years 56.5 (12.1)
 <65 years, n (%) 615 (71.1)
  ≥65 years, n (%) 250 (28.9)
Body mass indexa N = 818
  Mean (SD), kg/m2 27.5 (5.8)
  <25 kg/m2, n (%) 310 (37.9)
  25– < 30 kg/m2, n (%) 275 (33.6)
  30– < 35 kg/m2, n (%) 154 (18.8)
  ≥35 kg/m2, n (%) 79 (9.7)
Sex N = 865
 Men, n (%) 146 (16.9)
  Women, n (%) 719 (83.1)
Country N = 865
  Canada, n (%) 163 (18.8)
  Germany, n (%) 370 (42.8)
  Greece, n (%) 110 (12.7)
  Italy, n (%) 222 (25.7)
Disease characteristics
RA duration N = 842
  Mean (SD), years 11.4 (8.7)
 ≤2 years, n (%) 83 (9.9)
  3–5 years, n (%) 169 (20.1)
  6–10 years, n (%) 224 (26.6)
  >10 years, n (%) 366 (43.5)
Tender joint count/28 N = 848
  Mean (SD) 11.4 (7.3)
Swollen joint count/28 N = 858
  Mean (SD) 7.9 (5.9)
HAQ-DI N = 796
 <1.50, n (%) 332 (41.7)
  ≥1.50, n (%) 464 (58.3)
DAS28 (ESR, otherwise CRP) N = 793
  Remission or LDAS (≤3.2), n (%) 24 (3.0)
  MDAS (>3.2–5.1), n (%) 203 (25.6)
  HDAS (>5.1), n (%) 440 (55.5)
  Not done, n (%) 126 (15.9)
CDAI (calculated) N = 865
  Remission, LDAS, or MDAS (≤22), n (%) 196 (22.7)
  HDAS (>22), n (%) 568 (65.7)
  Missing, n (%) 101 (11.7)
Radiographic erosion (presence) N = 750
  No, n (%) 218 (29.1)
  Yes, n (%) 532 (70.9)
CRP N = 865
  <4 mg/L, n (%) 224 (25.9)
  4– < 10 mg/L, n (%) 172 (19.9)
  10– < 26 mg/L, n (%) 204 (23.6)
  ≥26 mg/L, n (%) 182 (21.0)
  Not done, n (%) 83 (9.6)
RF status N = 852
 Negative, n (%) 225 (26.4)
  Positive, n (%) 494 (58.0)
  Not available, n (%) 133 (15.6)
Anti-CCP status N = 834
  Negative, n (%) 162 (19.4)
  Positive, n (%) 294 (35.3)
  Not available, n (%) 378 (45.3)
Comorbidities
Cardiovascular disorders N = 865
  No, n (%) 807 (93.3)
  Yes, n (%) 58 (6.7)
  Cardiac arrhythmia, n (%) 22 (2.5)
  Cardiac valve disorder, n (%) 9 (1.0)
  Coronary artery disorder, n (%) 23 (2.7)
  Heart failure, n (%) 15 (1.7)
  Myocardial disorder, n (%) 2 (0.2)
COPD N = 865
  No, n (%) 803 (92.8)
  Yes, n (%) 62 (7.2)
Diabetes mellitus N = 865
 No, n (%) 753 (87.1)
  Yes, n (%) 112 (12.9)
Tobacco use N = 865
  No, n (%) 757 (87.5)
  Yes, n (%) 108 (12.5)
Infections and infestations N = 865
  No, n (%) 809 (93.5)
  Yes, n (%) 56 (6.5)
  1. Category in italics is the reference for univariate and multivariate analyses
  2. The analysis population included patients treated in Canada, Germany, Greece, and Italy who had received at least one prior biologic agent and had a baseline clinical assessment no later than 8 days after the first administration of abatacept
  3. CCP cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS Disease Activity Score, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, HDAS high Disease Activity Score, LDAS low Disease Activity Score, MDAS moderate Disease Activity Score, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation
  4. aWorld Health Organization body mass index classification: underweight/normal if <25 kg/m2, overweight if 25– < 30 kg/m2, obese class I if 30– < 35 kg/m2, and obese class II/III if ≥35 kg/m2 [21]